Inventor · disambiguated record
Carl Alexander Kamb
Also filed as: KAMB CARL ALEXANDER
16 granted patents·26 pending applications·339 citations·filing 1996–2023
93Inventor score
Files withA2 BIOTHERAPEUTICS INC22ARCARIS INC7DELTAGEN PROTEOMICS INC3AMGEN INC1DELTAGEN PROTEOMICS1
Top patents by PatentIndex Score
42 records- 0196US11254726B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Feb 22, 2022·16 cites·16 claims
- 0290US12195513B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 14, 2025·1 cites·18 claims
- 0390US12187775B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 7, 2025·1 cites·38 claims
- 0490US6025485AMethods and compositions for peptide libraries displayed on light-emitting scaffoldsARCARIS INC·Filed 1997·Granted Feb 15, 2000·144 cites·12 claims
- 0585US11602544B2Compositions and methods for treating EGFR positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Mar 14, 2023·1 cites·27 claims
- 0684US5955275AMethods for identifying nucleic acid sequences encoding agents that affect cellular phenotypesARCARIS INC·Filed 1997·Granted Sep 21, 1999·91 cites·29 claims
- 0782US11433100B2Compositions and methods for treating ceacam positive cancersA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Sep 6, 2022·1 cites·30 claims
- 0880US6582899B1Methods for identifying agents that cause a lethal phenotype, and agents thereofDELTAGEN PROTEOMICS INC·Filed 2000·Granted Jun 24, 2003·9 cites·30 claims
- 0979US12037377B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jul 16, 2024·0 cites·24 claims
- 1071US5998136ASelection systems and methods for identifying genes and gene products involved in cell proliferationARCARIS INC·Filed 1996·Granted Dec 7, 1999·44 cites·28 claims
- 1171US2023029341A1Nucleic acid encoding lilrb1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1270US11602543B2Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Mar 14, 2023·0 cites·27 claims
- 1368US2023277590A1Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1467US2024075067A1Compositions and methods for treating her2 positive cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1566US2023277593A1Compositions and methods for treating egfr positive cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1665US12435124B2Compositions and methods for treating CEACAM positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Oct 7, 2025·0 cites·19 claims
- 1765US11730764B2Compositions and methods for treating HER2 positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Aug 22, 2023·0 cites·22 claims
- 1864US6579675B2Methods for identifying nucleic acid sequences encoding agents that effect cellular phenotypesDELTAGEN PROTEOMICS INC·Filed 1999·Granted Jun 17, 2003·21 cites·23 claims
- 1960US2025177445A1Engineered receptors specific to hla-e and methods of useA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2059US2024180969A1Polypeptides targeting hla-a*11 and methods of use thereofA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2159US2022370498A1Immune cells expressing receptor specific to class i mhc molecule and interfering rna for hla geneA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2258US2025269027A1Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2357US2022315931A1Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin geneA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2455US2002098503A1Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypesFiled 2001·Application pending·0 cites
- 2554US2024000938A1Adoptive cell therapy for treatment of cancer associated with loss of heterozygosityA2 BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2652US2024173352A1Cell-surface receptors responsive to loss of heterozygosityA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2750US2015201588A1Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related MethodsAMGEN INC·Filed 2013·Application pending·0 cites
- 2850US2002172965A1Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefromARCARIS INC·Filed 2002·Application pending·0 cites
- 2949US2022389075A1Engineered t cell receptors and uses thereofA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3049US2023257441A1Compositions and methods for treating cancersA2 BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3148US2002090605A1Methods for identifying, characterizing, and evolving cell-type specific cis regulatory elementsFiled 2001·Application pending·0 cites
- 3248US2003027214A1Methods for substrate-ligand interaction screeningFiled 2002·Application pending·0 cites
- 3345US2002031790A1Methods for validating polypeptide targets that correlate to cellular phenotypesARCARIS INC·Filed 2001·Application pending·0 cites
- 3445US2002177125A1Human rhinovirus assays, and compositions therefromFiled 2001·Application pending·0 cites
- 3544US2002081688A1Retinoid pathway assays, and compositions therefromFiled 2001·Application pending·0 cites
- 3643US2003054389A1Methods for identifying agents that induce a cellular phenotype, and compositions thereofFiled 2002·Application pending·0 cites
- 3743US2002086386A1B-catenin assays, and compositions therefromFiled 2001·Application pending·0 cites
- 3841US2002019005A1Process for identification of genes encoding proteins having cell proliferation-promoting activityARCARIS INC·Filed 2001·Application pending·0 cites
- 3941US2002132229A1Process for identification of genes, perturbagens and cellular targets relating to viral growth and diseaseARCARIS INC·Filed 2001·Application pending·0 cites
- 4038US6623922B1Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elementsDELTAGEN PROTEOMICS·Filed 1997·Granted Sep 23, 2003·7 cites·12 claims
- 4137US2002045188A1Methods for validating polypeptide targets that correlate to cellular phenotypesFiled 2001·Application pending·0 cites
- 4235US6566057B1Methods and compositions for peptide libraries displayed on light-emitting scaffoldsDELTAGEN PROTEOMICS INC·Filed 1998·Granted May 20, 2003·3 cites·42 claims
Join the waitlist — get patent alerts
Get an alert when Carl Alexander Kamb files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →